Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Researchers and Healthcare Providers
 Research Grants Program
-Medical and Scientific Advisory Council
 Recent Recommendations
 What is MASAC?
 All MASAC Recommendations
 MASAC Members
 Nursing Working Group
 Social Work Working Group
 Physical Therapy Working Group
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Cell Based Coagulation Animation
 Rare Bleeding and Clotting Disorders Resource Room
 The Partners in Bleeding Disorders Education Program
 NHF/Novo Nordisk HANDI Library

 

 

 
MASAC Recommendation #91 - MASAC Recommendation Regarding Risk of Germline Trans
 

MASAC Recommendation #91

MASAC Recommendation Regarding Risk of Germline Transmission in Gene Therapy Trials for Hemophilia

The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on February 27, 1999, and adopted by the NHF Board of Directors on February 28, 1999.

The National Hemophilia Foundation supports gene therapy as the most promising strategy for curing hemophilia. At this time, NHF also supports the position advocated in the Orkin-Motulsky report on gene therapy that gene therapy should be somatic only, i.e. there should be no attempt to alter the germline cells. In assessing potential for inadvertent germline transmission, NHF agrees with an approach that classifies protocols into one of three groups based on pre-clinical studies, i.e. absence of vector sequences in gonads, transient positivity, or persistent positivity in the gonads, with recommendations for appropriate subjects for inclusion in a trial to be made on that basis. NHF believes that this risk, like other potential risks, should be weighed against the potential benefits to be realized from successful gene therapy for hemophilia. We urge the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health to allow protocols to proceed with appropriate monitoring and safeguards.